← Leaderboards
John P Cooke
University Of Tx Md Anderson Can Ctr
$32,967,803
Attributed
$42,268,748
Total exposure
28
Grants
17
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $4.7M · FY2005–25$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$44,482,026 · 29
By mechanism
R01$22,371,502 · 11
U01$7,369,877 · 1
U19$4,336,111 · 1
K12$2,954,354 · 1
RC2$2,696,700 · 1
T32$2,658,569 · 2
Top collaborators
- Kaifu Chen8 shared
- Jun-Ichi Abe7 shared
- Nhat-Tu Le7 shared
- Peter A Campochiaro4 shared
- John H Connor4 shared
- Abhishek Jain4 shared
- Craig N Morrell4 shared
- Ronald L Dalman3 shared
Most similar at University Of Tx Md Anderson Can Ctr
Same institution · by research overlap
- Jun-Ichi Abe$17,528,597
- Nhat-Tu Le$3,369,101
Others in their field
Top investigators on “Insight”
- Sonia M Thomas · Research Triangle Institute$701,865,642
- Tracy L Nolen · Research Triangle Institute$474,487,152
- James Dennis Neaton · Northwestern University$283,212,546
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$278,513,775
- Chanza Baytop · Westat, Inc.$271,217,917
- Richard K. Wilson · Washington University$200,435,757
Research focus
InsightEndothelial CellsPathway InteractionsBlood VesselsMolecularCellsBaseIn VitroProteinsLeadClinical ResearchIn VivoInnovationMediatingEpigenetic ProcessCell NucleusMitochondriaFibroblastsNitric Oxide SynthasePhenotypePlayHuman SubjectDoseEvent
Grant awards (88)
CORE E: RNA Manufacturing Core$4,002,763
U19 · FY2025 · AI · contact PI
Premature aging disorders, metabolites, and atherosclerosis$712,298
R01 · FY2025 · HL
Determinants of COVID19-induced venous thrombosis and targeted therapy assessed with bioengineered vein-chip$705,488
R01 · FY2024 · HL
Premature aging disorders, metabolites, and atherosclerosis$704,737
R01 · FY2024 · HL
CORE E: RNA Manufacturing Core$333,348
U19 · FY2024 · AI · contact PI
Premature aging disorders, metabolites, and atherosclerosis$756,681
R01 · FY2023 · HL
Determinants of COVID19-induced venous thrombosis and targeted therapy assessed with bioengineered vein-chip$732,287
R01 · FY2023 · HL
Reversal of Heart Failure: Role of Vascular Recovery$710,878
R01 · FY2023 · HL · contact PI
Pathological flow-induced endothelial damage and plaque erosion$782,390
R01 · FY2022 · HL
Reversal of Heart Failure: Role of Vascular Recovery$710,878
R01 · FY2022 · HL · contact PI
Determinants of COVID19-induced venous thrombosis and targeted therapy assessed with bioengineered vein-chip$665,322
R01 · FY2022 · HL
Pathological flow-induced endothelial damage and plaque erosion$788,251
R01 · FY2021 · HL
Determinants of COVID19-induced venous thrombosis and targeted therapy assessed with bioengineered vein-chip$721,633
R01 · FY2021 · HL
Reversal of Heart Failure: Role of Vascular Recovery$710,878
R01 · FY2021 · HL · contact PI
Role of S-nitrosylation in Transdifferentiation$403,750
R01 · FY2021 · HL · contact PI
Pathological flow-induced endothelial damage and plaque erosion$793,939
R01 · FY2020 · HL
Reversal of Heart Failure: Role of Vascular Recovery$710,878
R01 · FY2020 · HL · contact PI
Role of S-nitrosylation in Transdifferentiation$403,750
R01 · FY2020 · HL · contact PI
Pathological flow-induced endothelial damage and plaque erosion$829,206
R01 · FY2019 · HL
Role of S-nitrosylation in Transdifferentiation$403,750
R01 · FY2019 · HL · contact PI
Role of S-nitrosylation in Transdifferentiation$403,750
R01 · FY2018 · HL · contact PI
Basic and Translational Research iPSC-based hematologic and vascular therapies$861,527
U01 · FY2015 · HL · contact PI
Basic and Translational Research iPSC-based hematologic and vascular therapies$857,523
U01 · FY2014 · HL · contact PI
The Role of the Nicotinic Cholinergic Pathway in Retinopathy of Prematurity$393,837
R01 · FY2014 · EY · contact PI
Basic and Translational Research iPSC-based hematologic and vascular therapies$797,222
U01 · FY2013 · HL · contact PI
The Role of the Nicotinic Cholinergic Pathway in Retinopathy of Prematurity$381,134
R01 · FY2013 · EY · contact PI
Basic and Translational Research iPSC-based hematologic and vascular therapies$1,204,118
U01 · FY2012 · HL · contact PI
Cell Characterization and Imaging for Regenerative Therapies in Ischemic Diseases$534,435
UM1 · FY2012 · HL · contact PI
The Role of the Nicotinic Cholinergic Pathway in Retinopathy of Prematurity$405,202
R01 · FY2012 · EY · contact PI
Mechanisms in Innovation in Vascular Disease$369,814
T32 · FY2012 · HL
Basic and Translational Research iPSC-based hematologic and vascular therapies$1,188,317
U01 · FY2011 · HL · contact PI
Stanford Career Development in Vascular Medicine$807,332
K12 · FY2011 · HL · contact PI
The Role of the Nicotinic Cholinergic Pathway in Retinopathy of Prematurity$414,079
R01 · FY2011 · EY · contact PI
Mechanisms in Innovation in Vascular Disease$242,499
T32 · FY2011 · HL
Basic and Translational Research iPSC-based hematologic and vascular therapies$49,566
U01 · FY2011 · HL · contact PI
NCE-based strategy for nuclear reprogramming and regenerative medicine$1,346,802
RC2 · FY2010 · HL · contact PI
Basic and Translational Research iPSC-based hematologic and vascular therapies$1,176,639
U01 · FY2010 · HL · contact PI
CORE--Clinical Research Skills Development$162,949
P50 · FY2010 · HL · contact PI
Mechanisms in Innovation in Vascular Disease$119,254
T32 · FY2010 · HL
Basic and Translational Research iPSC-based hematologic and vascular therapies$33,900
U01 · FY2010 · HL · contact PI
NCE-based strategy for nuclear reprogramming and regenerative medicine$1,349,898
RC2 · FY2009 · HL · contact PI
Basic and Translational Research iPSC-based hematologic and vascular therapies$1,201,065
U01 · FY2009 · HL · contact PI
Stanford Career Development in Vascular Medicine$1,169,481
K12 · FY2009 · HL · contact PI
CORE--Clinical Research Skills Development$160,411
P50 · FY2009 · HL · contact PI
Translational research and education in cell therapies for vascular regeneration$39,500
R03 · FY2009 · HL · contact PI
Stanford Career Development in Vascular Medicine$643,130
K12 · FY2008 · HL · contact PI
Signal-transduction of Endothelial nAChR in Angiogenesis$233,708
R01 · FY2008 · CA · contact PI
CORE--Clinical Research Skills Development$167,121
P50 · FY2008 · HL · contact PI
Genetic Determinants of PAD$947,092
R01 · FY2007 · HL · contact PI
Stanford Career Development in Vascular Medicine$334,411
K12 · FY2007 · HL · contact PI
Stanford Vascular Biology and Medicine Training Grant$261,240
T32 · FY2007 · HL · contact PI
Signal-transduction of Endothelial nAChR in Angiogenesis$233,708
R01 · FY2007 · CA · contact PI
ADMA: An endogenous inhibitor of ESC differentiation and EC regeneration$189,412
R21 · FY2007 · HL · contact PI
THERAPEUTIC MANIPULATION OF THE NOS PATHWAY IN PERIPHERAL ARTERIAL DISEASE$14,628
M01 · FY2007 · RR · contact PI
Genetic Determinants of PAD$977,500
R01 · FY2006 · HL · contact PI
Stanford Vascular Biology and Medicine Training Grant$346,221
T32 · FY2006 · HL · contact PI
Signal-transduction of Endothelial nAChR in Angiogenesis$240,688
R01 · FY2006 · CA · contact PI
ADMA: An endogenous inhibitor ESC differentiation and EC$218,529
R21 · FY2006 · HL · contact PI
THERAPEUTIC MANIPULATION OF THE NOS PATHWAY IN PERIPHERAL ARTERIAL DISEASE$170,351
M01 · FY2006 · RR · contact PI
CORE--Clinical Research Skills Development$88,159
P50 · FY2006 · HL · contact PI
EFFECT OF ADMA AND L-ARGININE$1,779
M01 · FY2006 · RR · contact PI
Genetic Determinants of PAD$1,000,247
R01 · FY2005 · HL
Stanford Vascular Biology and Medicine Training Grant$346,221
T32 · FY2005 · HL
Signal-transduction of Endothelial nAChR in Angiogenesis$248,060
R01 · FY2005 · CA
THERAPEUTIC MANIPULATION OF THE NOS PATHWAY IN PERIPHERAL ARTERIAL DISEASE$193,118
M01 · FY2005 · RR
DEVELOPMENT OF INSULIN RESISTANCE IN PATIENTS WITH PERIPHERAL ARTERIAL DISEASE$7,685
M01 · FY2005 · RR
HEART TRANSPLANT PATIENTS - ROLE OF DYSREGULATION OF THE NITRIC OXIDE SYNTHASE$4,009
M01 · FY2005 · RR
Genetic Determinants of PAD$999,964
R01 · FY2004 · HL
MANIPULATION OF THE NOS PATHWAY IN ARTERIAL DISEASE$492,343
R01 · FY2004 · HL
Stanford Vascular Biology and Medicine Training Grant$346,221
T32 · FY2004 · HL
Double-Blind Placebo-Controlled Study of Oral L-arginine$132,455
M01 · FY2004 · RR
Genetic Determinants of PAD$32,534
R01 · FY2004 · HL
Manipulation of the NOS Pathway in Arterial Disease-Dose-Ranging Study.$9,779
M01 · FY2004 · RR
Peripheral Endothelial Vasomotor Function in Transplants$593
M01 · FY2004 · RR
Phase 2: Nos Pathway In Arterial Disease$0
R01 · FY2004 · HL
Manipulation Of The Nos Pathway In Arterial Disease$0
R01 · FY2004 · HL
Genetic Determinants of PAD$999,727
R01 · FY2003 · HL
MANIPULATION OF THE NOS PATHWAY IN ARTERIAL DISEASE$478,003
R01 · FY2003 · HL
Stanford Vascular Biology and Medicine Training Grant$341,789
T32 · FY2003 · HL
Manipulation Of The Nos Pathway In Arterial Disease$0
R01 · FY2003 · HL
Phase 2: NOs pathway in arterial disease$0
R01 · FY2003 · HL
MANIPULATION OF THE NOS PATHWAY IN ARTERIAL DISEASE$467,501
R01 · FY2002 · HL
CMV and dysregulation of the NOS pathway$0
P01 · FY2002 · AI
MANIPULATION OF THE NOS PATHWAY IN ARTERIAL DISEASE$414,765
R01 · FY2001 · HL
STANFORD VASCULAR BIOLOGY &MEDICINE TRAINING GRANT$53,681
T32 · FY2001 · HL
CMV and dysregulation of the NOS pathway$0
P01 · FY2001 · AI
MANIPULATION OF THE NOS PATHWAY IN ARTERIAL DISEASE$360,666
R01 · FY2000 · HL
STANFORD VASCULAR BIOLOGY &MEDICINE TRAINING GRANT$231,629
T32 · FY2000 · HL